Beyond Air, Inc. (NASDAQ:XAIR – Get Free Report) CFO Daniel Moorhead acquired 4,340 shares of the company’s stock in a transaction dated Wednesday, July 29th. The shares were bought at an average cost of $5.76 per share, for a total transaction of $24,998.40. Following the completion of the acquisition, the chief financial officer directly owned 4,340 shares of the company’s stock, valued at approximately $24,998.40. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Beyond Air Price Performance
NASDAQ XAIR opened at $5.28 on Monday. The company has a debt-to-equity ratio of 3.48, a current ratio of 3.80 and a quick ratio of 3.59. The stock’s fifty day moving average price is $7.69 and its 200 day moving average price is $14.19. Beyond Air, Inc. has a 1 year low of $5.02 and a 1 year high of $95.60. The company has a market cap of $3.81 million, a price-to-earnings ratio of -0.06 and a beta of 0.22.
Beyond Air (NASDAQ:XAIR – Get Free Report) last issued its quarterly earnings results on Friday, June 26th. The company reported ($15.40) EPS for the quarter, missing analysts’ consensus estimates of ($11.33) by ($4.07). Beyond Air had a negative return on equity of 350.00% and a negative net margin of 432.99%.The firm had revenue of $1.91 million for the quarter, compared to analyst estimates of $2.30 million.
Institutional Investors Weigh In On Beyond Air
Analysts Set New Price Targets
Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Beyond Air in a research note on Tuesday, July 21st. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $200.00.
View Our Latest Stock Analysis on Beyond Air
Beyond Air Company Profile
Beyond Air, Inc is a clinical-stage medical technology company focused on the development and commercialization of inhaled nitric oxide (NO) therapy for pulmonary and respiratory diseases. The company’s proprietary LungFit® platform delivers pulsed, low-dose nitric oxide gas through compact, portable devices designed to support treatments in both inpatient and outpatient settings. Beyond Air’s approach leverages NO’s antimicrobial, vasodilatory and anti-inflammatory properties to address a range of unmet needs in respiratory medicine.
The company’s lead candidate, LungFit® PH, is under investigation for the treatment of pulmonary hypertension, with ongoing clinical studies assessing its impact on pulmonary arterial pressure and exercise capacity.
Recommended Stories
- Five stocks we like better than Beyond Air
- 3 Fixed-Income ETFs Show Why Yield Is Only Part of the Income Story
- AbbVie Quietly Solved Its Biggest Problem—Now What?
- Rio Tinto’s Results Make the Case for Looking Beyond Tech in the AI Trade
- Strategy’s Structural Strength: Hidden in a $8 Billion Illusion
Receive News & Ratings for Beyond Air Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beyond Air and related companies with MarketBeat.com's FREE daily email newsletter.
